New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 23, 2014
07:30 EDTSYNSynthetic reports preclinical data to support clinical development of mAb
Synthetic Biologics announced positive preclinical research findings for SYN-005, the company's proprietary monoclonal antibody, or mAb, combination therapy for treating Pertussis. In the second pertussis study in particular, SYN-005 was associated with favorable decreases in white blood cell counts within two days and the achievement of nearly normal levels within one week. Based on positive non-human primate and murine model findings, Synthetic Biologics has filed an additional patent application around pertussis antibodies, intends to move into cGMP manufacturing of SYN-005, and intends to file an Investigational New Drug application to support a Phase I clinical trial expected to initiate during the first half of 2015. The Company also intends to request an Orphan Drug designation for SYN-005 for the treatment of Pertussis.
News For SYN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 22, 2014
06:59 EDTSYNSynthetic Biologics granted patent for C. difficile
Synthetic Biologics has been issued a Notice of Allowance by the USPTO for a composition of matter patent application that covers the lead product in its C. difficile program, SYN-004. This is Synthetic Biologics' first allowed patent application directly pertaining to SYN-004 in the U.S. SYN-004 is Synthetic Biologics' novel oral enzyme drug candidate designed as the first and only prophylactic treatment intended to prevent the development of C. difficile infections.
October 20, 2014
17:18 EDTSYNGreat Point Partners reports 9.98% passive stake in Synthetic Biologics
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use